SMO and nevoid basal cell carcinoma syndrome: Moreover, the utility of SMO inhibitors, including sonidegib and vismodegib, has proven to be clinically beneficial for the treatment of nonadvanced BCCs in NBCCS patients [176] and for the long-term intermittent treatment of multiple nonadvanced BCCs, including those with NBCCS [160], which warrants further study.